Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement.
Krawczyk P, Grenda A, Terlecka P, Błach J, Wojas-Krawczyk K, Kucharczyk T, Chmielewska I, Kieszko R, Jarosz B, Gil M, Reszka K, Milanowski J.
Krawczyk P, et al. Among authors: chmielewska i.
Sci Rep. 2021 Oct 22;11(1):20939. doi: 10.1038/s41598-021-00309-3.
Sci Rep. 2021.
PMID: 34686712
Free PMC article.